Skip to content

Jean-Paul Nutraceutical ColloRX Advance Lanosterol Eye Drop

Availability: Translation missing: en.general.icons.icon_check_circle icon 8 in stock, ready to be shipped

Notify me when back in stock

Jean-Paul Nutraceutical (JPN) ColloRX Advance Lanosterol Eye Drop (10ml)

Lanosterol is the only eye drop on the planet currently that has a real therapeutic effect on cataracts.

New Reformulated!
Advance Lanosterol Eye Drops with hyaluronic Acid as an aid in the management of cataracts. With improved lubrication and enhanced residual effects of Lanosterol; this formulation boasts the same great efficacy with more comfort for sensitive patients.


Hyaluronic Acid (HA) is a glycosaminoglycan (GAG) already present in the eye's aqueous humor and vitreous. When added to lanosterol, it helps with viscoelasticity thus reduces friction between the cornea and eyelids during blinking, thereby reducing mechanical stress and corneal injury. HA has a strong affinity for water molecules, allowing it to bind and retain water molecules effectively. This promotes the repair of corneal epithelial abrasions by stimulating epithelial cell adhesion, proliferation, migration, and overall epithelial healing.

Product will be packaged as 10ml with ColloRX 

Note: This is a fragile item and requires refrigeration. Contents should be used within two months of opening and application and discarded thereafter.

Product Information

Cataracts affect thousands of dogs around the world and is the leading cause of blindness. Cataracts are formed from cross-linking, a process whereby glycated proteins bind with other proteins and form large insoluble amounts of damaged protein that can accumulate in and disrupt the natural arrangement of the lens crystallin fibres. Factors that contribute to this cross-linking include inflammation, inflammatory cytokines produced in generalized allergies, food sensitivities and environmental factors such as excessive direct UV exposure. Currently the only real solution is surgery as many other earlier therapeutic eye drops (1,2,3,4,5,6) for cataracts has shown only limited success.

Lanosterol has shown to be the only compound implicated as a potential agent to reverse and ‘dissolve’ cataracts in dogs as shown by Zhao et al. in 2015 (7). They discovered mutations in lanosterol synthase (LSS) that contributed to congenital cataracts in three children from a Caucasian family. LSS synthesizes lanosterol which is a naturally occurring steroid in the lens. It is similar to cholesterol. Lanosterol is a tetracyclic triterpenoid and is the compound from which all animal and fungal steroids are derived.

Molecular Formula: C30H50O
It is an amphipathic molecule, i.e. it is both hydrophilic and hydrophobic.
In Zhao’s in vitro study, lens tissues from rabbits were immersed in solution of lanosterol for six days in the dark at room temperature; whilst in the in vivo study, dogs’ eyes received intravitreal injections of lanosterol loaded nanoparticles as well as topical lanosterol drops and the outcomes were measured six weeks later. The degree of cataract assessed by lens clarity before and after the treatment periods was assessed by blinded examiners using an opacification grading system. They found a statistically significant reduction in cataract severity and improvement in lens clarity post-treatment in both studies. They concluded that lanosterol inhibits lens protein aggregation by coating the hydrophobic core areas of large protein aggregates within the lens, thus rendering them water-soluble which improves their clarity.
However currently the implications for human cataract remains unclear Shanmugam et al. in 2015 (8).


  • Wash hands before use.
  • Shake well (slight flocculation may occur if left standing for too long) before applying
  • One drop to affected eyes 3-4 x a day. Frequency can be reduced to 2 x a day for prophylaxis.
  • Keep refrigerated.
  • Discard any unused portions after 30 days of opening

Avoid any contact of dropper tip with any surface or eye. Discard bottle if any discolouration or large flocculants appear in the solution.

A slight stinging may be experienced by a few patients on initial instillation of the eye drop. This sensation is only transient. If prolonged irritation occurs, this may mean that the patient may have a sensitivity to the drops and it should be discontinued immediately and a health care professional consulted.

Liquid error (layout/theme line 287): Could not find asset snippets/expo.liquid